Acalabrutinib is indicated for:
Population group: both men and women, only adults (18 years old or older)
Acalabrutinib is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: both men and women, only adults (18 years old or older)
Acalabrutinib is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL).
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: both men and women, only adults (18 years old or older)
Acalabrutinib is indicated for the treatment of adult patients with small lymphocytic lymphoma (SLL).
For this indication, competent medicine agencies globally authorize below treatments (click for details):